BRCA1 and cancer: For example, RDGVs in BRCA1 and BRCA2 were, as expected, significantly enriched in OV and BRCA compared to in all the other cancer samples (BRCA1, excess of RDGVs in BRCA compared to non-breast cancer = 2.1%, 95% CI: 1.1–3.1%, excess in OV = 6.7%, 5.1–8.2%; BRCA2, excess in BRCA = 1.3%, 0.49–2.1%; excess in OV = 3.9%, 2.7–5.1%).